PRNewswire

February 2, 2026

Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites

read more →

PRNewswire

January 21, 2026

Crystalys Therapeutics Expands Leadership Team with Appointment of Justin Thacker as Chief Financial Officer to Support Advancement of Phase 3 Trials of Dotinurad

read more →

PR Newswire

October 21, 2025

Crystalys Therapeutics Advances Phase 3 Trials of Dotinurad for the Treatment of Gout with Dosing of First Patients

read more →

September 30, 2025

Crystalys Therapeutics Launches with $205M Series A Financing to Transform the Treatment of Gout

read more →